Northland Capital partners view: Dosing of first patients always represents a major milestone in phase 3 trials, as it confirms that preparations have gone to plan and that there are no major delays. Management also indicated that patient recruitment is on target.
Clinical trial update: first patients dosed |
n ImmuPharma announced that the first US sites for its pivotal phase 3 study of its flagship Lupus treatment, Lupuzor™, have commenced dosing patients.
n Recruitment will occur in up to 45 investigator sites—10 sites in United States and 35 in Europe. |